Therapeutic Strategies For Interstitial Lung Diseases In Rheumatoid Arthritis
Published 2018 · Medicine
Download PDFAnalyze on Scholarcy
Pulmonary involvement is common in rheumatoid arthritis (RA) and affects all components of the lung. Interstitial lung disease (ILD) is the most predominant pulmonary manifestation and has been identified as the main cause of morbidity and mortality in RA. There are distinct histological and/or radiological subtypes in RA-associated ILD (RA-ILD) with different clinical phenotypes and natural courses. An optimal treatment for RA-ILD has not yet been established, because there have been no randomized controlled trials on RA-ILD. Current therapeutic regimens typically include corticosteroids with or without immunosuppressive drugs; however, supporting evidence is limited by the small numbers of patients and uncontrolled study designs. Several novel agents, such as rituximab, pirfenidone, and nintedanib, are currently under investigation. Furthermore, optimal treatments may differ depending on the histological and/or radiological subtypes of RA-ILD. In order to address these issues, prospective controlled studies with a large number of RA-ILD patients are urgently needed. In this chapter, the treatment of RA-ILD will be described by overviewing recent studies in this field, and the best available evidence to inform a treatment rationale will be provided.
This paper references
Efficacy of intensive immunosuppression in exacerbated rheumatoid arthritis-associated interstitial lung disease
Mineto Ota (2017)
Progressive preclinical interstitial lung disease in rheumatoid arthritis.
B. R. Gochuico (2008)
Cyclosporine A combined with low-dose corticosteroid treatment in patients with idiopathic pulmonary fibrosis.
Yasunari Miyazaki (2015)
Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study.
C. Kelly (2014)
Cyclophosphamide versus placebo in scleroderma lung disease.
D. Tashkin (2006)
Interstitial lung disease in rheumatoid arthritis: response to IL-6R blockade
M. Mohr (2011)
Treatment with Etanercept in a Patient with Rheumatoid Arthritis-Associated Interstitial Lung Disease
Y. Wang (2011)
Rituximab in autoimmune connective tissue disease-associated interstitial lung disease.
Charles Sharp (2016)
A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease.
D. Daoussis (2017)
Successful use of cyclosporin A for the treatment of acute interstitial pneumonitis associated with rheumatoid arthritis.
D. Ogawa (2000)
Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease.
J. Swigris (2006)
Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
A. Azuma (2005)
Pulmonary involvement in rheumatoid arthritis.
J. Anaya (1995)
Interstitial lung disease related to rheumatoid arthritis: evolution after treatment.
J. Rojas-Serrano (2012)
Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: a retrospective case control study
H. Hozumi (2013)
Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review.
C. Roubille (2014)
Tacrolimus in refractory poly myositis with inter stitial lung disease
Chester V Oddis (1999)
Possible effect of abatacept on the progression of interstitial lung disease in rheumatoid arthritis patients.
Tamao Nakashita (2016)
Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study
D. Daoussis (2010)
198. MORTALITY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INTERSTITIAL LUNG DISEASE TREATED WITH TUMOUR NECROSIS FACTOR INHIBITOR OR RITUXIMAB
K. Druce (2017)
Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-related Interstitial Lung Disease: Scleroderma Lung Study II (SLS-II), a double-blind, parallel group, randomised controlled trial
D. Tashkin (2016)
Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease
D. J. Go (2015)
Survival and quality of life in rheumatoid arthritis-associated interstitial lung disease after lung transplantation.
Arash Yazdani (2014)
Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis.
S. Bosello (2015)
Usefulness of Cyclophosphamide Pulse Therapy in Interstitial Lung Diseases
J. Schupp (2016)
Exacerbation of combined pulmonary fibrosis and emphysema syndrome during tocilizumab therapy for rheumatoid arthritis.
D. Wendling (2013)
Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab
Wan-Hee Yoo (2009)
Characteristic features of tacrolimus-induced lung disease in rheumatoid arthritis patients
Takanori Sasaki (2015)
Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease.
K. Antoniou (2007)
Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis.
S. Ochi (2005)
Diffuse interstitial pulmonary fibrosis associated with arthritis, with comments on the definition of rheumatoid lung disease.
Snider Gl (1962)
A case report of rheumatoid arthritis complicated with rapidly progressive interstitial pneumonia, multiple bullae and pneumomediastinum, which was successfully treated with tacrolimus.
S. Ochi (2008)
Successful treatment of progressive rheumatoid interstitial lung disease with cyclosporine: a case report.
H. Chang (2002)
Effects of rituximab in connective tissue disorders related interstitial lung disease.
G. Lepri (2016)
Extra-articular manifestations of rheumatoid arthritis: An update.
M. Prete (2011)
The efficacy of tacrolimus in patients with refractory dermatomyositis/polymyositis: a systematic review
Yongpeng Ge (2015)
Rituximab: rescue therapy in life-threatening complications or refractory autoimmune diseases: a single center experience
Yolanda Braun-Moscovici (2012)
Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis.
O. Nishiyama (2008)
Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis.
M. Johnson (1989)
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
T. King (2014)
Successful treatment with tacrolimus of progressive interstitial pneumonia associated with amyopathic dermatomyositis refractory to cyclosporine
M. Ando (2009)
Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition.
R. Vassallo (2002)
Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study
J. Curtis (2015)
A simultaneous onset of organizing pneumonia and rheumatoid arthritis, along with a review of the literature
S. Mori (2008)
Diffuse interstitial pulmonary fibrosis and rheumatoid arthritis.
W. Walker (1969)
Relationship of rheumatoid factor to lung diffusion capacity in smoking and non-smoking patients with rheumatoid arthritis.
R. Luukkainen (1995)
092. Efficacy and Safety of Rituximab in Rheumatoid Arthritis Patients with Concomitant Interstitial Lung Disease: 10-Year Experience at Single Centre
A. Kabia (2015)
Effective Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease by B-Cell Targeted Therapy with Rituximab
W. Hartung (2012)
THU0158 Efficacy and Safety of Rituximab in Rheumatoid Arthritis Patients with Concomitant Interstitial Lung Disease: 10-Year Experience at Single Centre
MY Md Yusof (2015)
Use of tacrolimus, a potent antifibrotic agent, in bleomycin-induced lung fibrosis
J. Nagano (2006)
Biological treatments and connective tissue disease associated interstitial lung disease
S. Panopoulos (2011)
Step-up versus primary intensive approach to the treatment of interstitial pneumonia associated with dermatomyositis/polymyositis: a retrospective study
K. Takada (2007)
Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome
Yoshinori Tsuchiya (2010)
Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases.
R. Pérez-Álvarez (2011)
Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies
C. Nannini (2008)
Non-infectious pulmonary toxicity of rituximab: a systematic review.
A. V. Hadjinicolaou (2012)
Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort.
G. Koduri (2010)
Interstitial pneumonitis complicating rheumatoid arthritis. Sustained remission with azathioprine therapy.
J. Cohen (1977)
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.
G. Raghu (2015)
Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study.
T. Bongartz (2010)
Methotrexate and Lung Disease in Rheumatoid Arthritis: A Meta‐Analysis of Randomized Controlled Trials
R. Conway (2014)
A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab
S. Kawashiri (2010)
Experience of Mycophenolate Mofetil in 10 Patients With Autoimmune-Related Interstitial Lung Disease Demonstrates Promising Effects
L. Saketkoo (2009)
Cigarette smoking and rheumatoid arthritis severity
K. Saag (1997)
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
L. Richeldi (2014)
Tacrolimus-induced pulmonary injury in rheumatoid arthritis patients.
R. Koike (2011)
An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial
D. Khanna (2016)
Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case–control study
M. Akiyama (2016)
Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease
A. Holland (2008)
A Metaanalysis of the Increased Risk of Rheumatoid Arthritis-related Pulmonary Disease as a Result of Serum Anticitrullinated Protein Antibody Positivity
J. Zhu (2014)
Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab.
D. Mcgonagle (2008)
The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis.
T. Kurita (2015)
Pirfenidone in idiopathic pulmonary fibrosis
J. Swigris (2010)
Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.
S. Nathan (2017)
Organising pneumonia as the first manifestation of rheumatoid arthritis
C. Hoshino (2011)
In Vitro Evidence for a Direct Antifibrotic Role of the Immunosuppressive Drug Mycophenolate Mofetil
N. Roos (2007)
Rheumatoid arthritis interstitial lung disease: mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug.
L. Saketkoo (2008)
Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: a prospective study in patients who failed to respond to corticosteroids.
D. Zisman (2000)
Tacrolimus-induced lung injury in a rheumatoid arthritis patient with interstitial pneumonitis
Yusuke Miwa (2008)
Treatment of progressive rheumatoid interstitial lung disease with cyclosporine.
M. Puttick (1995)
Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis
E. Bargagli (2004)
Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease
E. Kim (2009)
Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years
C. Turesson (2003)
Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis.
D. Daoussis (2012)
Mycophenolate Mofetil Improves Lung Function in Connective Tissue Disease-associated Interstitial Lung Disease
A. Fischer (2013)
Rituximab for the treatment of connective tissue disease-associated interstitial lung disease.
S. Chartrand (2016)
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
P. Noble (2011)
Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease.
H. Lee (2005)
Abatacept therapy in rheumatoid arthritis with interstitial lung disease.
A. Mera-Varela (2014)